PMID: 7526894Aug 1, 1994Paper

IL-2 receptor alpha chain (CD25, TAC) expression defines a crucial stage in pre-B cell development

International Immunology
A RolinkF Melchers

Abstract

The analysis of the expression of the alpha chain of the IL-2 receptor (CD25, TAC) on the surface of B lineage cells in mouse bone marrow reveals that it is a useful marker to distinguish pre-B-I from pre-B-II cells. CD25 is not expressed on CD45R(B220)+ c-kit+ CD43+ TdT+ lambda 5+ c mu- sIg-IgH chain locus DJH-rearranged pre-B-I cells of mouse bone marrow. It is expressed on large cycling CD45R(B220)+ c-kit- CD43+ TdT- lambda 5+ c mu+ sIg- and on small resting CD45R(B220)+ c-kit- CD43- TdT- lambda 5- c mu- sIg- IgH chain locus VHDJH-rearranged pre-B-II cells. Therefore, the transition from pre-B-I to large pre-B-II cells is marked by the downregulation of c-kit and terminal deoxynucleotidyl transferase (TdT), and by the upregulation of CD25. SCID, RAG-2T, microMT and lambda 5T mutant mice do have normal, if not elevated numbers of pre-B-I cells but lack all CD25+ pre-B-II cells in their bone marrow. The expression of a transgenic H chain under control of the microH chain enhancer in RAG-2T bone marrow B lineage precursors allows the development of large and small CD25+ pre-B-II cells. The results suggest that the differentiation of pre-B-I to pre-B-II cells in mouse bone marrow requires the expression of microH chains and surr...Continue Reading

Citations

Jun 26, 1999·European Journal of Immunology·T BorggrefeR Jessberger
Sep 23, 2008·Immunologic Research·Hongsheng Wang, Herbert C Morse
Jun 1, 1995·Immunology Today·W C Lin, S Desiderio
Apr 1, 1995·Current Opinion in Immunology·F MelchersJ Andersson
Mar 14, 2003·International Journal for Parasitology·Ton That Ai LongHiroji Kanbara
Aug 13, 1998·Developmental and Comparative Immunology·H R Rodewald, C Haller
Dec 1, 1996·Immunology Letters·A Rolink, F Melchers
Jul 9, 1999·Immunology Letters·A G RolinkF Melchers
Mar 24, 1998·Immunology Today·D G OsmondF Melchers
Oct 24, 1998·Immunology Today·P GhiaF Melchers
Apr 18, 2000·Experimental Gerontology·P GhiaA G Rolink
Mar 14, 2000·Current Opinion in Immunology·M BusslingerA G Rolink
May 14, 1999·Current Opinion in Immunology·R J Benschop, J C Cambier
Sep 11, 2002·Seminars in Immunology·Inga-Lill MårtenssonTakeyuki Shimizu
Oct 22, 2002·Immunity·Michael SchebestaMeinrad Busslinger
Apr 1, 1997·Immunology and Cell Biology·H KarasuyamaK Kuida
Sep 10, 2013·Nature Immunology·Hilde SchjervenStephen T Smale
Apr 1, 1996·The Journal of Experimental Medicine·U GrawunderF Melchers
Aug 1, 1996·The Journal of Experimental Medicine·M AsanoS Sakaguchi
Aug 26, 1998·The Journal of Experimental Medicine·C ThéveninM Busslinger
Feb 24, 2000·The Journal of Experimental Medicine·F M Smart, A R Venkitaraman
Feb 22, 2001·The Journal of Experimental Medicine·C MundtI L Mårtensson
Dec 10, 2003·The Journal of Experimental Medicine·Theresa TretterStephen Desiderio
Feb 6, 2004·The Journal of Experimental Medicine·Yijin LiMartin Weigert
Nov 2, 2005·The Journal of Experimental Medicine·Bhaskar SrivastavaDavid Allman
Mar 1, 2006·The Journal of Experimental Medicine·Lynn L RumfeltRichard R Hardy
Jul 11, 2006·The Journal of Experimental Medicine·Heather L Van Epps
Mar 21, 2009·International Immunology·Hans Brightbill, Mark S Schlissel
Jan 7, 2003·Genes & Development·David G T HessleinDavid G Schatz
Jun 24, 1998·Genes & Development·R MostoslavskyY Bergman
Jan 10, 2002·Genome Research·Reinhard HoffmannFritz Melchers
Jan 9, 2008·Molecular and Cellular Biology·Yu ZhangPatrick Matthias

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.